TEva Pharmaceuticals Ltd’s Adderall shortage is expected to last through March, which is two to three months longer for the company. He said last weekaccording to US regulators.
A common treatment for attention-deficit/hyperactivity disorder has been unavailable since at least August, leaving people racing to fill prescriptions and find pharmacies with dodgy drugs in stock. Demand for the drug is at an all-time high, and Teva sells more Adderall in the United States than any other drug company.
Teva “Suffers Intermittent Delays in Manufacturing,” FDA He said on its website on Wednesday. While other companies are producing the drug, “there is not enough supply to continue to meet US market demand through these producers.”
Teva spokesman Kelly Dougherty said the company’s previous labor shortage, which has since been resolved, as well as increased drug demand and manufacturing limits set by the U.S. Drug Enforcement Administration have contributed to the shortage.
“We are working closely with our manufacturing facility and the DEA to see what additional volumes we may be able to support going forward,” Dougherty said.
Five doses of Teva’s generic immediate-release Adderall are on hold, with recovery expected in March, including the most popular 10mg, 20mg and 30mg pills, according to the Food and Drug Administration. Most Teva-branded immediate-release formulations are available, but 10 mg tablets are also in late demand, with recovery expected this month.
Nine companies in total have had trouble supplying Adderall lately.
The FDA lists three companies in addition to Teva that are in short supply — Epic Pharma LLC, Rhodes Pharmaceuticals LP (a subsidiary of Purdue Pharma LP), and SpecGX LLC (a subsidiary of Mallinckrodt Plc). Additionally, the University of Utah Drug Information Service, which tracks drug shortages, reported last week that Amneal Pharmaceuticals Inc. and Camber Pharmaceuticals Inc, Novartis AG’s Sandoz unit, Par Pharmaceutical (part of Endo International Plc), and Sun Pharmaceutical Industries Ltd. They were having trouble getting medicine.
More must-read stories from TIME